The company said fourth-quarter 2024 fiscal year revenue for Q4 rose 12% year over year to $59.9 billion, GAAP diluted EPS was $0.96, and non-GAAP diluted EPS increased 29% to $1.84.

1. 01

   The company said fourth-quarter 2024 fiscal year revenue for Q4 rose 12% year over year to $59.9 billion, GAAP diluted EPS was $0.96, and non-GAAP diluted EPS increased 29% to $1.84.

2. 02

   Cardinal Health said operating cash flow and adjusted free cash flow for fiscal 2024 both reached all-time highs of $3.8 billion and $3.9 billion, respectively, and it used $750 million for share repurchases in the same fiscal year.

3. 03

   Cardinal Health said it raised its fiscal 2025 non-GAAP diluted EPS outlook to $7.55 to $7.70 from at least $7.50, and increased its share repurchase outlook to $750M from $500M.

4. 04

   The company said segment profit for its Global Medical Products and Distribution segment in Q4 rose by $40 million to $47 million, and for the full year it was $92 million ($(147) million in the prior year). The company cited an improvement in net inflationary impacts as the driver of the increase in Q4.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.